Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Organon & Co.

< Previous 1 2 3 Next >
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
From Organon & Co.
Via Business Wire
Tickers OGN
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Third Quarter Ended September 30, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
From Organon & Co.
Via Business Wire
Tickers OGN
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Second Quarter Ended June 30, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
From Organon & Co.
Via Business Wire
Tickers OGN
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the First Quarter Ended March 31, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report First Quarter and Host Conference Call on May 4, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Third Quarter Ended September 30, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.